JF
ESPR

Jump Financial’s Esperion Therapeutics ESPR Stock Holding History

Jump Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-689,874
Closed -$1.89M – 2153
2026
Q1 		$1.89M Buy
+689,874
New +$2.18M 0.03% 677
2024
Q2 		– Sell
-38,762
Closed -$104K – 1925
2024
Q1 		$104K Buy
38,762
+12,939
+50% +$31.4K ﹤0.01% 1787
2023
Q4 		$77.2K Buy
+25,823
New +$33.5K ﹤0.01% 1687
2022
Q4 		– Sell
-56,600
Closed -$379K – 1699
2022
Q3 		$379K Sell
56,600
-5,400
-9% -$37.1K 0.01% 1021
2022
Q2 		$395K Buy
62,000
+7,400
+14% +$42K 0.02% 946
2022
Q1 		$253K Buy
+54,600
New +$234K 0.01% 1169
2021
Q4 		– Sell
-27,000
Closed -$326K – 1475
2021
Q3 		$326K Buy
+27,000
New +$393K 0.02% 623

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Jump Financial's ESPR Position: Q2 2026 in Review

Jump Financial sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 689,874 shares — an estimated $1.89M sold.

Jump Financial first reported a position in ESPR in Q3 2021 and held it in 7 quarters. The position peaked at $1.89M in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Jump Financial reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 689,874 Esperion Therapeutics shares in Q2 2026, an estimated $1.89M.
  • Jump Financial first reported a position in Esperion Therapeutics in Q3 2021 and held it in 7 quarters.
  • Jump Financial's Esperion Therapeutics position peaked at $1.89M in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.